10/29/2026
A recent study is offering hope for people with Stargardt disease, an inherited retinal condition that currently has no approved treatment. In clinical trials, an investigational oral pill slowed the progression of retinal atrophy over two years. While more research is needed, these findings are promising. Learn more: https://brnw.ch/21x6LmD
The TEASE-1 randomized clinical trial evaluates the safety and efficacy of oral gildeuretinol acetate on the growth of retinal atrophic lesions in individuals with Stargardt disease.